Nicox: Vyzulta approved in Mexico
(CercleFinance.com) - Ophthalmology laboratory Nicox announces that its licensed partner, Bausch + Lomb, has received marketing approval for Vyzulta in Mexico (latanoprostene bunod ophthalmic solution), 0.
024%.
Its approval in Mexico follows approvals in the United States and Canada. Vyzulta is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
The French biopharmaceutical company receives net royalties increasing from 6% to 12% on global sales of Vyzulta as well as future milestone payments of up to 150 million dollars.
The market clearly likes this news - the Nicox share is up over 4.5% in early trading on Monday.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
024%.
Its approval in Mexico follows approvals in the United States and Canada. Vyzulta is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
The French biopharmaceutical company receives net royalties increasing from 6% to 12% on global sales of Vyzulta as well as future milestone payments of up to 150 million dollars.
The market clearly likes this news - the Nicox share is up over 4.5% in early trading on Monday.
Copyright (c) 2020 CercleFinance.com. All rights reserved.